William R. Bishai, MD, PhD

Co-Director

Titles:

Co-Director, Center for Tuberculosis Research

Professor, Medicine,Pathology, and Molecular Microbiology Immunology

SciVal:

SciVal Link

Area of Research

Bacterial gene regulation, pathogenesis, tuberculosis, latent infections, sigma factors.

Specific Research Interests

Transcription factors regulate bacterial adaptive response for switching between rapid growth leading to overt disease and stationary phase survival during which the host is colonized and at risk for disease. We study the role of stationary phase-specific transcription factors in diseases caused by Mycobacterium tuberculosis and Staphylococcus aureus. Latent tuberculosis is a colonization state which affects one-third of the world’s population and carries a significant risk for active TB. M. tuberculosis possesses 12 alternate RNA polymerase sigma factors several of which govern virulence and persistence in animal models and survival in vitro under stationary phase and stress conditions. We are using molecular genetic strategies including microarray analysis with recombinant bacteria to characterize the roles of these transcription factors in diseases caused by M. tuberculosis. Testing of virulence and persistence is performed locally using either the mouse or rabbit models of tuberculosis.

Additionally, clinical research on TB has been an active interest in the laboratory, and we have ongoing collaborative projects with other members of the Center for Tuberculosis Research on experimental therapeutics and diagnostics, both in Baltimore City and in several foreign settings.

Staff & Students

Research Associate:

Post docs

PhD students

Categories

Events

«

June 2017

»
S
M
T
W
T
F
S
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·

Projects

Modeling the impact of spatially targeted TB...

 We have developed transmission models to understand the impact of TB vaccination strategies that target hotspots of...

Read More

A randomized trial of preventive therapy for...

We are evaluating the efficacy and cost-effectiveness of levofloxacin preventive therapy for pediatric contacts of MDR TB...

Read More

Understanding the costs and...

We have conducted an empirical costing analysis of facility-based versus community-based treatment for TB in Bangladesh and are...

Read More

Comparative implementation and...

We are conducting a randomized comparative implementation trial across 56 sites in rural South Africa to evaluate three...

Read More

TBM-KIDS (India)

A phase 2 clinical trial of optimized treatment for pediatric tuberculous meningitis in India and Malawi

Read More